Contact this trialFirst, we need to learn more about you.
Tyrosine Kinase Inhibitor
Nilotinib + Paclitaxel for Rare Cancers
Recruiting1 awardPhase 2
Bethesda, Maryland
This trial is testing if nilotinib and paclitaxel will help people with rare cancers. People with rare, advanced cancer that has progressed after receiving standard treatment, or for which no effective therapy exists, may be eligible. The drugs are given in 28-day cycles. Nilotinib is a capsule taken by mouth twice a day. Paclitaxel will be given intravenously by peripheral line or central line once a week for the first 3 weeks of each cycle.
Fill-in a few details and create your profileHaving a profile will help us send you recommended trials and speed up your application in the future.
We will keep your details privateWe won’t share unless you give us permission. By completing this form you agree to our privacy policy
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.